利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

741 条记录 (耗时 0.058 秒)

    Materials and methods for the detection of nitrated fibrinogen
    104.
    发明授权
    Materials and methods for the detection of nitrated fibrinogen 有权
    用于检测硝化纤维蛋白原的材料和方法

    公开(公告)号：US08852879B2

    公开(公告)日：2014-10-07

    申请号：US12168739

    申请日：2008-07-07

    申请人： Harry Ischiropoulos

    发明人： Harry Ischiropoulos

    IPC分类号： C12Q1/56 ,  G01N33/543 ,  A61K38/36 ,  A61K45/06 ,  A61K38/48 ,  G01N33/86 ,  A61K38/37 ,  G01N33/68 ,  C07K16/36

    CPC分类号： G01N33/6893 ,  A61K38/36 ,  A61K38/363 ,  A61K38/37 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/4866 ,  A61K45/06 ,  C07K16/36 ,  G01N33/543 ,  G01N33/68 ,  G01N33/86 ,  G01N2333/75 ,  G01N2800/226 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52 ,  A61K2300/00

    摘要： Compositions are disclosed comprising an effective amount of nitrated fibrinogen and a pharmaceutically acceptable carrier for detecting a patient's risk for coronary artery disease. The compositions can be used to determine the presence of nitrated fibrinogen which is linked with coronary artery disease. Also disclosed is a method for determining the presence or risk for coronary artery disease or risk for increased propensity for an adverse thrombotic event in a patient. The method comprises obtaining a sample of blood or fraction thereof from a patient; determining by immunoassay the amount of nitrated fibrinogen in the sample based on binding of the nitrated fibrinogen to an antibody that specifically recognizes SEQ ID NO: 2 and/or SEQ ID NO: 3; and comparing the amount of the antibody-bound nitrated fibrinogen in the sample with the amount of nitrated fibrinogen in a sample from a normal individual, such that a greater amount of nitrated fibrinogen in the patient sample than in the normal individual indicates that the patient has or is at greater risk of coronary artery disease or risk of increased propensity for an adverse thrombotic event. Kits for performing the method which include the composition and aforementioned antibody or antibodies are also provided.

    摘要翻译： 公开了组合物，其包含有效量的硝化纤维蛋白原和用于检测患者冠状动脉疾病风险的药学上可接受的载体。 该组合物可用于确定与冠状动脉疾病相关的硝化纤维蛋白原的存在。 还公开了一种用于确定冠状动脉疾病的存在或风险或患者中不良血栓形成事件倾向增加的风险的方法。 该方法包括从患者获得血液或其部分样品; 基于硝化纤维蛋白原与特异性识别SEQ ID NO：2和/或SEQ ID NO：3的抗体的结合免疫测定样品中硝化纤维蛋白原的量; 并将样品中抗体结合的硝化纤维蛋白原的量与来自正常个体的样品中的硝化纤维蛋白原的量进行比较，使得患者样品中比常规个体更大量的硝化纤维蛋白原表明患者具有 或者患冠状动脉疾病的风险更大或不利血栓事件倾向增加的风险。 还提供了用于进行包括组合物和上述抗体或抗体的方法的试剂盒。

    Methods of inhibiting alternative pathway complement activation with anti-factor D antibodies
    105.
    发明授权
    Methods of inhibiting alternative pathway complement activation with anti-factor D antibodies 有权
    用抗因子D抗体抑制替代途径补体激活的方法

    公开(公告)号：US08765131B2

    公开(公告)日：2014-07-01

    申请号：US13759743

    申请日：2013-02-05

    申请人： Genentech, Inc.

    发明人： Michael Fung ,  William N. C. Sun ,  Cecily R. Y. Sun

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/36

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76

    摘要： The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.

    摘要翻译： 本发明涉及与因子D结合并阻断因子D在补体激活中的功能活性的因子D抑制剂。 抑制剂包括抗体分子，以及同系物，类似物及其修饰或衍生形式，包括免疫球蛋白片段如Fab，F（ab'）2和Fv，小分子，包括肽，寡核苷酸，肽模拟物和有机化合物。 产生与因子D结合并阻断其激活补体的能力的单克隆抗体，并命名为166-32。 产生该抗体的杂交瘤保藏在American Type Culture Collection，10801 University Blvd.，Manassas，Va。20110-2209，登录号HB-12476。

    Single Domain VHH Antibodies Against Von Willebrand Factor
    107.
    发明申请
    Single Domain VHH Antibodies Against Von Willebrand Factor 审中-公开
    针对Von Willebrand因子的单域VHH抗体

    公开(公告)号：US20130136736A1

    公开(公告)日：2013-05-30

    申请号：US13734129

    申请日：2013-01-04

    申请人： Karen Silence

    发明人： Karen Silence

    IPC分类号： C07K16/36

    CPC分类号： C07K16/36 ,  A61K38/36 ,  A61K2039/505 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/473

    摘要： The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.

    摘要翻译： 本发明涉及针对血管性血友病因子（vWF）的改进的纳米抗体（TM），以及包含或基本上由一种或多种这样的纳米抗体组成的多肽。 本发明还涉及编码这种纳米抗体和多肽的核酸; 制备这种纳米抗体和多肽的方法; 宿主表达或能够表达这种纳米抗体或多肽的细胞; 包含这样的纳米抗体，多肽，核酸或宿主细胞的组合物; 以及这样的纳米抗体，这种多肽，这种核酸，这种宿主细胞或这种组合物的用途，特别是用于预防，治疗或诊断目的，例如预防，治疗或诊断目的。

    ANTI-FXI ANTIBODIES AND METHODS OF USE
    109.
    发明申请
    ANTI-FXI ANTIBODIES AND METHODS OF USE 有权
    抗FXI抗体及其使用方法

    公开(公告)号：US20110250207A1

    公开(公告)日：2011-10-13

    申请号：US13140115

    申请日：2009-12-18

    申请人： Andras Gruber ,  Erik I. Tucker ,  David Gailani

    发明人： Andras Gruber ,  Erik I. Tucker ,  David Gailani

    IPC分类号： A61K39/395 ,  A61P7/02 ,  C12N15/63 ,  C12N5/10 ,  C07K16/36 ,  C07H21/00

    CPC分类号： C07K16/36 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/76

    摘要： Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.

    摘要翻译： 本文公开的是针对因子XIIa（fXIIa）防止fXI激活的因子XI（fXI）特异性的单克隆抗体。 单克隆抗体是通用的fXI抗体，能够结合所有被检测的哺乳动物。 抗FXI单克隆抗体延长哺乳动物血浆中的凝血时间。 此外，本文公开的fXI单克隆抗体的施用导致血栓形成的抑制，而不改变血栓形成的动物模型中的止血。 因此，本文提供的是针对fXI特异性的阻断fXIIa的fXI活化的单克隆抗体，包含此类抗体的组合物和免疫缀合物及其使用方法。